Abstract��OBJECTIVE To identify the related substances in aituomode bulk drug. METHODS HPLC-QTrap-MS and HPLC-QTOF-MS were used to determine seven kinds of related substances denoted by Imp-A to Imp-G. RESULTS The structures and molecular weights of the related substances in aituomode were identified. CONCLUSION The method is simple and accurate, providing a good idea for the identification of the related substances in bulk drugs. The experimental data are valuable to the determination of the related substances and quality control of aituomode.
�����ã�����ͮ��Ф������������. HPLC-MS/MS��������ҩ�ﰬ��Ī�µ��й�����[J]. �й�ҩѧ��־, 2017, 52(1): 68-71.
ZHANG Ting-ting, JIN Bo, LI Tong, XIAO Qiong, YIN Da-li, MA Chen. Identification of Related Substances in a New Drug Aituomode by HPLC-MS/MS. Chinese Pharmaceutical Journal, 2017, 52(1): 68-71.
PARISI R, SYMMONS D P, GRIFITHS C E, et al. Global epidemiolog of psoriasis: a systenmtic review of incidence and prevalence . J Invest Dermatol, 2013, 133(2):377-385.
[2]
MATTOZZI C, SALVI M, D��EPIRO S, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature . Dermatology, 2013, 227(2):134-145.
[3]
GUENTHER L, GULLIVER W. Psoriasis comorbidities . J Cutan Med Surg, 2009, 13 (suppl 2):77-87.
[4]
STERN R S, NIJSTEN T, FELDMAN S, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction . J Investig Dermatol Symp, 2004, 9(2):136-139.
[5]
RAPP S R, FELDMAN S R, EXUM M L, et al. Psoriasis causes as much disability as other major medical diseases . J Am Acad Dermatol, 1999, 41(3):401-407.
[6]
FARLEY E. Psoriasis:comorbidities and associations . G Ital Dermatol Venereol, 2011, 146(1):9-15.
[7]
TAN J, WOLFE B. A patient decision aid for psoriasis based on current clinical practice guidelines . Arch Dermatol, 2012, 148(6):718-723.
[8]
YUE X A, ZOU Y. The progress on the treatment of psoriasis . J Dermatol Venereol(Ƥ�������Բ�), 2015, 37(4):207-209.
[9]
TIAN Y L, JIN J, WANG X J, et al. Design, synthesis and docking-based 3D-QSAR study of novel 2-substituted 2-aminopropane-1,3-diols as potent and selective agonists of sphingosine-1-phosphate 1 (S1P1) receptor . Med Chem Commu, 2013, 4(9):1267-1274. HANG W J, ZHANG H J, WANG X J, et al. Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof. China, 10370297.3. 20140402. JIN J,WANG X J, ZHOU W Q, et al. Pharmacological activity of a novel selective S1P1 agonist (prodrug) Syl978 . J China Pharm Univ(�й�ҩ�ƴ�ѧѧ��), 2014, 45(3):358-361. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities in New Drug Substances, Q3A. 2006. Guidance for Impurities in Chemical Drug Substances. Center for Drug Evalution. GPH 3-1.2005,3.
2017, Vol. 52 
